Telix Pharmaceuticals and Invicro have furthered their partnership to develop an artificial intelligence (AI) platform that will be called TelixAI for Telix's prostate-specific membrane antigen (PSMA)-PET imaging agent, Illuccix (gallium-68 gozetotide).
TelixAI will boost the efficiency and reproducibility of clinicians' imaging interpretations by categorizing healthy versus abnormal tracer uptake, according to the firm. The company is highlighting TelixAI at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting in Vancouver.
In other Telix news, Illuccix is now available in 139 U.S. pharmacies that are part of the Jubilant Radiopharma Network, it said.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
